Serum GLP-1 as a Novel Biomarker for Endometrial Cancer Detection in Obese Women
Highlight
- Serum GLP-1 levels decrease progressively from endometrial polyp through hyperplasia to endometrial cancer in obese, non-diabetic women.
- Lower GLP-1 levels independently predict presence of endometrial cancer with high diagnostic accuracy (AUC 0.94).
- GLP-1 correlates negatively with age and systemic inflammation marker CRP, but its cancer association persists after adjustment.
- Potential utility of GLP-1 as an adjunct biomarker for risk stratification in obese women with abnormal uterine bleeding.
Study Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.